The lancet oncology
-
The lancet oncology · Dec 2014
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy. In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma. ⋯ Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical International Company.
-
The lancet oncology · Dec 2014
Practice GuidelineGlobal uptake of BHGI guidelines for breast cancer.